Why is Edwards Lifesciences Corporation stock rising?
Final U.S. TAVR national coverage determination policy is expected in September 2026, potentially improving Medicare coverage and patient access.
PROGRESS trial results in moderate aortic stenosis are expected at TCT later in 2026, potentially opening a larger TAVR patient population.
Next-generation PASCAL with Capture Clarity technology is expected to be approved in the U.S. and Europe in Q4 2026.
PASCAL is expected to launch in the U.S. for tricuspid patients in Q4 2026, adding a new indication and market.
Edwards plans a major U.S. rollout of its ECLIPTIS surgical left atrial appendage technology later in 2026.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Edwards Lifesciences Corporation and 4,900+ companies.